{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:20:21Z","timestamp":1790061621813,"version":"4.0.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ejca.2024.113601","type":"journal-article","created":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T01:36:54Z","timestamp":1707010614000},"page":"113601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Real-world health-related quality of life outcomes for patients with resected stage III\/IV melanoma treated with adjuvant anti-PD1 therapy"],"prefix":"10.1016","volume":"200","author":[{"given":"Mees","family":"Egeler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5388-1695","authenticated-orcid":false,"given":"Julia","family":"Lai-Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Tissier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7974-8422","authenticated-orcid":false,"given":"Itske","family":"Fraterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Kuijpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winan","family":"Van Houdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Wilgenhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2540-2009","authenticated-orcid":false,"given":"Rebecca","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9218-617X","authenticated-orcid":false,"given":"Kelly","family":"de Ligt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3262-6935","authenticated-orcid":false,"given":"Alexander","family":"van Akkooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0413-6872","authenticated-orcid":false,"given":"Lonneke","family":"van de Poll-Franse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejca.2024.113601_bib1","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ejca.2024.113601_bib2","first-page":"OF1","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage iii\/iv melanoma: 5-year efficacy and biomarker results from CheckMate 238","author":"Larkin","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2024.113601_bib3","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(23)00233-4","article-title":"Adjuvant immune checkpoint blockade revisited","volume":"24","author":"van Doorn","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.113601_bib4","article-title":"The \u201cgreat debate\u201d at melanoma bridge 2022, Naples, December 1st\u20133rd, 2022","author":"Ascierto","year":"2023","journal-title":"BioMed Cent"},{"key":"10.1016\/j.ejca.2024.113601_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103919","article-title":"Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: a systematic scoping review","author":"Egeler","year":"2023","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"5","key":"10.1016\/j.ejca.2024.113601_bib6","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic immune-related adverse events following adjuvant anti\u2013PD-1 therapy for high-risk resected melanoma","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2024.113601_bib7","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.9591","article-title":"Long-term outcomes of chronic immune-related adverse events from adjuvant anti-PD-1 therapy for high-risk resected melanoma","volume":"41","author":"Goodman","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2024.113601_bib8","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/eurheartj\/ehaa884","article-title":"The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study","volume":"42","author":"D\u2019Souza","year":"2021","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.ejca.2024.113601_bib9","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ejca.2024.113601_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejca.2020.03.016","article-title":"Adjuvant immunotherapy: the sting in the tail","volume":"132","author":"Higham","year":"2020","journal-title":"Eur J Cancer"},{"issue":"10336","key":"10.1016\/j.ejca.2024.113601_bib11","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"issue":"17_suppl","key":"10.1016\/j.ejca.2024.113601_bib12","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA9500","article-title":"Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: The phase 3 KEYNOTE-716 study","volume":"40","author":"Long","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.113601_bib13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(21)00081-4","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Bottomley","year":"2021","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2024.113601_bib14","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.113601_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2023.02.005","article-title":"Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review","volume":"184","author":"Lai-Kwon","year":"2023","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2024.113601_bib16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/0284186X.2023.2165449","article-title":"Quality of life and mental health in real-world patients with resected stage III\/IV melanoma receiving adjuvant immunotherapy","volume":"62","author":"Pedersen","year":"2023","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2024.113601_bib17","doi-asserted-by":"crossref","first-page":"S916","DOI":"10.1016\/j.annonc.2022.07.936","article-title":"810P PRESERV MEL: Real-world outcomes and health-related quality of life (HRQoL) in patients receiving adjuvant nivolumab for melanoma in Belgium and Luxembourg","volume":"33","author":"Rogiers","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.113601_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/POR.S350165","article-title":"Measuring health-related quality of life in randomised controlled trials: expected and reported results do not match","author":"Wiedemann","year":"2022","journal-title":"Pragmatic Obs Res"},{"issue":"6","key":"10.1016\/j.ejca.2024.113601_bib19","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2024.113601_bib20","unstructured":"Institute, N.C. PROMs in de Spreekkamer. 2020 [cited 2024 19\u201301]; Available from: https:\/\/www.nki.nl\/research\/research-groups\/lonneke-van-de-poll\/our-research\/proms-in-de-spreekkamer\/#:%E2%88%BC:text=Nowadays%2C%20PROMs%20are%20more%20and,the%20daily%20clinical%20hospital%20practice."},{"key":"10.1016\/j.ejca.2024.113601_bib21","unstructured":"Victoria, M.R. Melanoma Research Victoria. 2010 [cited 2024 19\u201301]; Available from: https:\/\/melanomaresearchvic.com.au\/about-us."},{"key":"10.1016\/j.ejca.2024.113601_bib22","unstructured":"EMA, report-workshop-health-related-quality-life-oncology. 2012."},{"issue":"5","key":"10.1016\/j.ejca.2024.113601_bib23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2024.113601_bib24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2022.10.026","article-title":"Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer","volume":"178","author":"Cocks","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.113601_bib25","unstructured":"Fayers, P., et al., EORTC QLQ\u2013C30 scoring manual. 1995: European Organisation for research and treatment of cancer."},{"key":"10.1016\/j.ejca.2024.113601_bib26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jclinepi.2015.08.007","article-title":"Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust","volume":"69","author":"Giesinger","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"394","key":"10.1016\/j.ejca.2024.113601_bib27","first-page":"165","article-title":"RStudio: integrated development environment for R. Boston","volume":"770","author":"Allaire","year":"2012","journal-title":"MA"},{"key":"10.1016\/j.ejca.2024.113601_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejca.2018.09.005","article-title":"Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma","volume":"104","author":"Musoro","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.113601_bib29","doi-asserted-by":"crossref","unstructured":"Bates, D., et al., Fitting linear mixed-effects models using lme4. arXiv preprint arXiv:1406.5823, 2014.","DOI":"10.18637\/jss.v067.i01"},{"issue":"9","key":"10.1016\/j.ejca.2024.113601_bib30","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/2041-210X.13434","article-title":"Robustness of linear mixed\u2010effects models to violations of distributional assumptions.","volume":"11","author":"Schielzeth","year":"2020","journal-title":"Methods Ecol Evol"},{"key":"10.1016\/j.ejca.2024.113601_bib31","author":"Lee","year":"2004","journal-title":"Cond Marg Model: Another view"},{"issue":"18","key":"10.1016\/j.ejca.2024.113601_bib32","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.ejca.2015.08.027","article-title":"The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients","volume":"51","author":"Quinten","year":"2015","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2024.113601_bib33","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0959-8049(00)00134-9","article-title":"Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist","volume":"36","author":"Kramer","year":"2000","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2024.113601_bib34","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0959-8049(00)00144-1","article-title":"Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer","volume":"36","author":"Kramer","year":"2000","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2024.113601_bib35","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S1470-2045(16)30510-1","article-title":"Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards","volume":"17","author":"Bottomley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.113601_bib36","author":"Younger","year":"2018","journal-title":"Health-Relat Qual life Patients Sarcoma: Enhancing Pers Med"},{"issue":"2","key":"10.1016\/j.ejca.2024.113601_bib37","first-page":"805","article-title":"Negative correlations of psychological distress with quality of life and immunotherapy efficacy in patients with advanced NSCLC","volume":"12","author":"Bi","year":"2022","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ejca.2024.113601_bib38","doi-asserted-by":"crossref","unstructured":"Reijers, I.L., et al., The impact of emotional distress on pathologic response and survival after neoadjuvant combination immune checkpoint blockade (ICB) in high-risk stage III melanoma. 2023, American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2023.41.16_suppl.9558"},{"issue":"2","key":"10.1016\/j.ejca.2024.113601_bib39","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.113601_bib40","first-page":"1","article-title":"Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma","author":"Fraterman","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.ejca.2024.113601_bib41","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1200\/JCO.2011.40.8922","article-title":"Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis","volume":"31","author":"Faller","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113601_bib42","first-page":"1563","article-title":"The effectiveness of mindfulness-based interventions among cancer patients and survivors: a systematic review and meta-analysis","volume":"28","author":"Xunlin","year":"2020","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2024.113601_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101155","article-title":"Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline","volume":"8","author":"Grassi","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2024.113601_bib44","unstructured":"Egeler, M., et al. Phase I of the Development of an EORTC QOL Module for Patients with Advanced Melanoma. in QUALITY OF LIFE RESEARCH. 2022. SPRINGER VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS."},{"issue":"3","key":"10.1016\/j.ejca.2024.113601_bib45","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.1793","article-title":"Prevalence of missing data in the national cancer database and association with overall survival","volume":"4","author":"Yang","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"19","key":"10.1016\/j.ejca.2024.113601_bib46","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage iii melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2024.113601_bib47","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.113601_bib48","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40273-016-0389-9","article-title":"Health, health-related quality of life, and quality of life: what is the difference?","volume":"34","author":"Karimi","year":"2016","journal-title":"Pharmacoeconomics"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:43:15Z","timestamp":1760733795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924000777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":48,"alternative-id":["S0959804924000777"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113601","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world health-related quality of life outcomes for patients with resected stage III\/IV melanoma treated with adjuvant anti-PD1 therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113601"}}